Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD
2024-516902-46-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), recurrent depressive disorder (RDD) and bipolar disorder (BD) (6 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Effect of methylphenidate on task vs. rest activation in task-defined, methylphenidate-reactive brain regions. Planned start Sep 2024; status: authorised.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)recurrent depressive disorder (RDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2024-516902-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516902-46-00.